16 October 2019
Visiongain has launched a new pharma report ‘’Myeloproliferative Disorders Drugs Market Report 2020-2030’’ by Type (Chronic Eosinophilic Leukemia/Hypereosinophilic Syndrome (HES), Essential Thrombocythemia (ET), Primary myelofibrosis, Polycythemia Vera (PV), Systemic Mastocytosis (SM)), Drug Type (Anti-Neoplastics, JAK2 Inhibitor, Demethylation Agents, Imatinib Mesylate, Others), Distribution Channel (Drug Stores, Hospitals Pharmacies), and Geography
The global Myeloproliferative Disorders Drugs market is anticipated to grow at a lucrative CAGR of 3.7% and anticipated to surpass USD 11 Billion by 2030.
Myeloproliferative disorders are a group of slow-growing blood cancers where too many abnormal red blood cells (RBC), white blood cells (WBC), or platelets accumulate in the blood are produced by the bone marrow. The type of myeloproliferative disease is based on whether too many RBC, WBC or platelets are being made. Sometimes, the body will create too many more than one type of blood cell, but one form of blood cell is generally more affected than the others.
Few types of myeloproliferative disorders which include:
Chronic eosinophilic leukemia: This rare cancer happens when too many eosinophils (a sort of WBC) are made by the bone marrow.
Essential thrombocythemia: This is platelet overproduction, making the blood too sticky. This form of MPD may result in blood vessels being obstructed, which may trigger a heart attack or stroke.
Primary myelofibrosis (also called chronic idiopathic myelofibrosis): The bone marrow produces too much collagen in this disease thus limiting the marrow's capacity to generate blood cells.
Polycythemia vera: Polycythemia vera is heavily connected with a genetic mutation.
The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders. The increased incidence of myeloproliferative disorders and the existence of a sturdy product pipeline is boosting the growth of myeloproliferative disorders drugs market across the globe. Growing geriatric population, lifestyle change and increasing awareness among the general population are anticipated to further drive the growth of the global market.
Different clinical trials are being conducted to treat myeloproliferative disorders which would further boost the market growth. However, high drug and therapy costs along with a lack of awareness among the population in developing and developing countries are hampering the growth of this industry.
North America holds the majority of market share owing to the presence of major pharmaceutical players undertaking various R&D activities, government initiative, and an increase in R&D development funding for myeloproliferative disorders. Europe is projected to contribute for the second in terms of market share and revenue, owing to an emerging treatment option, development of oncology drug discovery and growing prevalence of myeloproliferative disorders.
Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the increasing number of vascular surgeons and the low cost of peripheral interventions. In the Asia Pacific region, China is projected to register the highest growth owing to a significant increase in the investments in research for developing new drugs. MEA and Latin America are projected to exhibit sluggish growth in myeloproliferative disorders drugs over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global myeloproliferative disorder drugs market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.
The comprehensive market report features companies such as Bristol-Myers Squibb, Inctye, Novartis, Pfizer, Takeda, Teva Pharmaceutical Industries Ltd. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.
09 September 2020
The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.